Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective

This publication doesn't include Faculty of Arts. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors

PŘIKRYL Radovan PŘIKRYLOVÁ KUČEROVÁ Hana VRZALOVÁ Michaela ČEŠKOVÁ Eva

Year of publication 2012
Type Article in Periodical
Magazine / Source Schizophrenia Research and Treatment
MU Faculty or unit

Central European Institute of Technology

Citation
Web http://www.hindawi.com/journals/sprt/2012/764769/
Doi http://dx.doi.org/10.1155/2012/764769
Field Psychiatry, sexuology
Keywords first episode schizophrenia; injectable; second generation antipsychotics;
Attached files
Description Approximately 80% of patients with the first-episode schizophrenia reach symptomatic remission after antipsychotic therapy. However, within two years most of them relapse, mainly due to low levels of insight into the illness and nonadherence to their oral medication. Therefore, although the formal data available is limited, many experts recommend prescribing long-acting injectable second-generation antipsychotics (mostly risperidone or alternatively paliperidone) in the early stages of schizophrenia, particularly in patients who have benefited from the original oral molecule in the past and agree to receive long-term injectable treatment. Early application of long-acting injectable second-generation antipsychotics can significantly reduce the risk of relapse in the future and thus improve not only the social and working potential of patients with schizophrenia but also their quality of life.
Related projects: